上海市医院抗肿瘤药物畅销品种点评
摘要
本文根据上海市81家样本医院提供2006-2008年抗肿瘤用药畅销品种、金额数据等，结合临床应用进行分析点评。畅销品种有奥沙利铂、紫杉醇、紫杉特尔、卡培池滨、吉西他滨、表柔比星等，其需求量增长迅速，新型靶向药物利多昔单抗、吉非替尼等虽然价格昂贵，但前蓄看好由此可见开发高效、低毒、价臁的抗肿瘤药物是当今迫切的任务。
出处
《中国医药技术经济与管理》
2010年第4期30-34,共5页
China Pharmaceutical Technology Economics & Management
参考文献5
-
1Bianco R,Melisi D,Ciardiello F,et aI.Key cancer cell signal transduction pathways as therapeutic targets[J]. Eur J Cancer,2006,42(3):290-294,.
-
2勇威本.利妥昔单抗治疗B细胞淋巴瘤现状[J].世界临床药物,2007,28(5):274-277. 被引量：7
-
3Wong SF.Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment ofcolorectal cancer [J]. Clin Ther,2005,27(6):684-694.
-
4Kalofonos HP,Grivas PD.Monoclonal antibodies in the management of solid tumors[J]. Curr Top Med Chem,2006,6(16):1687-1705.
-
5张阳,张力.永无止境的探索——从临床研究看肺癌研究的新进展[J].中国处方药,2007,6(8):61-62. 被引量：3
二级参考文献10
-
1Kaminski M S,Tuck M,Estes J,et al.131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma[].The New England Journal of Medicine.2005
-
2Conconi A,Martinelli G,Thieblemont C,et al.Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type[].Blood.2003
-
3Gopal AK,Gooley TA,Maloney DG,et al.High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma[].Blood.2003
-
4Cheson BD.Radioimmunotherapy of non-Hodgkin lymphomas[].Current Drug Targets.2006
-
5Marcus R,Imrie K,Belch A,et al.CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma[].Blood.2005
-
6Hiddemann W,Kneba M,Dreyling M,et al.Frontline therapy with rituximab addedto the combination of cyclophosphamide,doxorubicin,vincrestine,and prednisone(CHOP)significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone[].Blood.2005
-
7Gheilmini M,Schimitz SF,Cogliatti SB,et al.Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x4schedule[].Blood.2004
-
8Czuczman MS,Weaver R,Alkuzweny B,et al.Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy:9-year follow-up[].Journal of Clinical Oncology.2004
-
9Witzig TE,Flinn IW,Gordon LI,et al.Treatment.with ibritumomab tiuxetan radioimmunotherapy inpatients with rituximab-refractory follicular non-Hodgkin’s lymphoma[].Journal of Clinical Oncology.2002
-
10Lenz G,Dreyling M,Hoster E,et al.Immunochemotherapy with rituximab and cyclophosphamide,doxorubicin,vincristine,and prednisone significantly improves response and time to treatment failure,but not long-term outcome in patients with previously untreated mantle cell lymphoma[].Journal of Clinical Oncology.2005
共引文献6
-
1何凤贞,刘淑英.美罗华治疗B细胞淋巴瘤不良反应的预防及护理[J].天津护理,2009,17(6):330-331. 被引量：6
-
2申邢.利妥昔单抗滴注致过敏反应的预防与护理[J].安徽医药,2010,14(8):982-983.
-
3徐红冰,归成.2006-2008年上海市81家样本医院抗肿瘤药物应用分析[J].中国医院药学杂志,2010,30(24):2117-2120.
-
4刘红,张关敏,张艳华.29例利妥昔单抗注射液不良反应的临床观察与分析[J].中国医院药学杂志,2011,31(5):429-431. 被引量：6
-
5李文娟.美罗华联合CHOP方案治疗淋巴瘤的观察与护理[J].中国肿瘤外科杂志,2011,3(4):253-254.
-
6归成,徐红冰,黄堃.2009-2011年上海医院抗肿瘤用药分析[J].上海医药,2013,34(11):27-30. 被引量：5
-
1张军.紫杉特尔的临床药理研究[J].国外医药（合成药．生化药．制剂分册）,1995,16(6):342-343. 被引量：2
-
2裴建明,陶仲为.非小细胞肺癌治疗新药紫杉特尔[J].齐鲁肿瘤杂志,1996,3(1):46-46.
-
3卞益民,赖水招,金燕辛.紫杉烷类抗癌新药—紫杉特尔的研究进展[J].广东药学,2000,10(1):3-5. 被引量：4
-
4宫萍,国大亮.2003年日本上市的新药(第Ⅰ部分)抗肿瘤药[J].齐鲁药事,2004,23(2):62-62. 被引量：5
-
5林英城,吴名耀,李德锐.紫杉特尔诱导肿瘤细胞凋亡机制研究进展[J].国外医学（肿瘤学分册）,2001,28(5):342-344.
-
6徐红冰,归成.2006-2008年上海市81家样本医院抗肿瘤药物应用分析[J].中国医院药学杂志,2010,30(24):2117-2120.
-
7归成.上海医院用药畅销品种点评[J].中国医药技术经济与管理,2011(1):28-32.
-
8郭海英.“保胃”品类战犹酣[J].中国药店,2008(3):60-61.
-
9归成,徐红冰,寿佳慧.上海市医院补钙剂及活性维生素D的应用分析[J].中国药房,1999,10(5):220-221. 被引量：2
-
10郝春芳,江泽飞,宋三泰.紫杉特尔在乳腺癌化疗中的应用[J].国外医学（肿瘤学分册）,2003,30(2):129-132. 被引量：37
